Re-occurring genetic alterations identified in AML are mutations in components of the signal transduction (e.g. FLT3, KIT, KRAS, NRAS), nulceophosmin-1 (NPM1), myeloid transcription factors, chromatin modifiers, tumor suppressors (e.g. TP53, WT1) and genes associated with DNA methylation (e.g. TET1, TET2, IDH1, IDH2, DNMT3B, DNMT1, DNMT3A) as well as gene fusions involving transcription factors. Here, TP53 is linked to acute myeloid leukemia.